Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price Target & Predictions
LXRX Stock Forecast
Lexicon Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LXRX Analyst Ratings
According to 3 Wall Street analysts, Lexicon Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for LXRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 17, 2024 | H.C. Wainwright | - | Buy | Initialise |
| May 31, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 01, 2022 | Citigroup | Buy | Buy | Hold |
Lexicon Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 03, 2024. The company gave LXRX a "Buy" rating, the same as its previous rate.
Lexicon Pharmaceuticals Financial Forecast
Lexicon Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $702.00K | $162.00K | $317.00K | $24.00K | $28.00K | $39.00K | - | $37.00K | $14.00K | $23.00K | $234.00K | $27.00K | $199.00K | $6.63M | $9.16M | $8.00M | $8.73M | $294.45M | $9.68M | $9.22M | $6.86M | $13.75M |
| Avg Forecast | $20.60M | $19.19M | $16.94M | $14.81M | $8.41M | $5.22M | $3.44M | $1.40M | $1.25M | $2.06M | $66.67K | $33.33K | $50.00K | $50.00K | $100.00K | $50.00K | $14.78K | $120.00K | $13.50K | $2.23M | $66.67K | $91.34M | $8.84M | $7.78M | $10.26M | $12.00M | $28.52M | $13.29M | $8.84M | $14.22M |
| High Forecast | $66.53M | $61.98M | $54.73M | $47.84M | $27.15M | $13.38M | $11.10M | $4.52M | $1.40M | $6.65M | $215.33K | $107.66K | $161.49K | $161.49K | $100.00K | $59.45K | $17.73K | $144.00K | $16.05K | $2.66M | $79.26K | $108.60M | $10.50M | $9.25M | $12.20M | $14.26M | $33.91M | $15.80M | $10.61M | $17.06M |
| Low Forecast | $9.47M | $8.82M | $7.79M | $6.81M | $3.86M | $1.91M | $1.58M | $643.68K | $1.10M | $947.21K | $30.65K | $15.32K | $22.99K | $22.99K | $100.00K | $40.22K | $11.82K | $96.00K | $10.86K | $1.80M | $53.62K | $73.47M | $7.11M | $6.26M | $8.26M | $9.65M | $22.94M | $10.69M | $7.07M | $11.37M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 3 | 8 | 13 | 11 | 10 | 10 | 9 | 8 | 10 | 9 | 6 | 11 | 6 | 14 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | 0.56% | 0.08% | 4.75% | 0.72% | 0.56% | 0.78% | - | 0.74% | 0.95% | 0.19% | 17.33% | 0.01% | 2.98% | 0.07% | 1.04% | 1.03% | 0.85% | 24.55% | 0.34% | 0.69% | 0.78% | 0.97% |
Lexicon Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.40M, with a low forecast of $643.68K, and a high forecast of $4.52M. LXRX's average Quarter revenue forecast represents a 99.43% increase compared to the company's last Quarter revenue of $702.00K (Dec 23).
Lexicon Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 3 | 8 | 13 | 11 | 10 | 10 | 9 | 8 | 10 | 9 | 6 | 11 | 6 | 14 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | $-46.74M | $-49.63M | $-44.24M | $-30.11M | $-29.39M | $-22.41M | - | $-23.26M | $-25.32M | $-22.85M | $-17.86M | $-20.75M | $-4.98M | $87.50M | $-63.05M | $-60.57M | $-45.01M | $226.18M | $-16.94M | $-15.78M | $-21.34M | $-28.59M |
| Avg Forecast | $-14.26M | $-13.28M | $-11.73M | $-10.25M | $-5.82M | $-3.61M | $-2.38M | $-20.33M | $-865.96K | $-1.43M | $-46.15K | $-21.75M | $-34.62K | $-23.74M | $-69.23K | $-23.26M | $-26.72M | $-25.39M | $-21.20M | $-22.05M | $-46.15K | $63.95M | $-58.91M | $-65.84M | $-7.11M | $-8.30M | $-12.71M | $-16.50M | $-25.87M | $-29.43M |
| High Forecast | $-6.56M | $-6.11M | $-5.39M | $-4.71M | $-2.68M | $-1.32M | $-1.09M | $-16.27M | $-764.08K | $-655.75K | $-21.22K | $-17.40M | $-15.91K | $-18.99M | $-69.23K | $-18.61M | $-21.38M | $-20.31M | $-16.96M | $-17.64M | $-37.12K | $76.74M | $-47.13M | $-52.67M | $-5.72M | $-6.68M | $-10.17M | $-13.20M | $-20.70M | $-23.55M |
| Low Forecast | $-46.06M | $-42.91M | $-37.89M | $-33.12M | $-18.80M | $-9.27M | $-7.68M | $-24.40M | $-967.84K | $-4.61M | $-149.07K | $-26.09M | $-111.80K | $-28.49M | $-69.23K | $-27.91M | $-32.07M | $-30.47M | $-25.44M | $-26.46M | $-54.87K | $51.16M | $-70.69M | $-79.01M | $-8.45M | $-9.87M | $-15.25M | $-19.80M | $-31.04M | $-35.32M |
| Surprise % | - | - | - | - | - | - | - | - | 53.97% | 34.80% | 958.55% | 1.38% | 849.08% | 0.94% | - | 1.00% | 0.95% | 0.90% | 0.84% | 0.94% | 107.92% | 1.37% | 1.07% | 0.92% | 6.33% | -27.24% | 1.33% | 0.96% | 0.83% | 0.97% |
10 analysts predict LXRX's average Quarter EBITDA for Dec 20 to be $-46.15K, with a high of $-37.12K and a low of $-54.87K. This is -100.05% lower than Lexicon Pharmaceuticals's previous annual EBITDA (Sep 20) of $87.50M.
Lexicon Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 3 | 8 | 13 | 11 | 10 | 10 | 9 | 8 | 10 | 9 | 6 | 11 | 6 | 14 | 19 |
| Net Income | - | - | - | - | - | - | - | - | $-48.24M | $-50.52M | $-44.90M | $-30.91M | $-30.71M | $-23.68M | - | $-23.57M | $-25.60M | $-23.12M | $-18.07M | $-20.96M | $-5.50M | $82.60M | $-69.07M | $-66.61M | $-51.14M | $226.09M | $-23.02M | $-21.80M | $-27.51M | $-34.71M |
| Avg Forecast | $-49.73M | $-51.29M | $-49.73M | $-48.18M | $-49.50M | $-48.55M | $-55.01M | $-20.52M | $-67.50M | $-66.72M | $-54.29M | $-21.95M | $-41.61M | $-24.02M | $-39.53M | $-23.48M | $-27.03M | $-25.69M | $-21.45M | $-22.27M | $-67.75M | $60.36M | $-64.54M | $-72.40M | $-188.94M | $151.76M | $-17.26M | $-22.79M | $-33.35M | $-35.73M |
| High Forecast | $-14.81M | $-15.27M | $-14.81M | $-14.34M | $-14.74M | $-42.48M | $-16.38M | $-16.42M | $-61.64M | $-19.86M | $-16.16M | $-17.56M | $-12.39M | $-19.22M | $-39.53M | $-18.78M | $-21.63M | $-20.55M | $-17.16M | $-17.81M | $-50.52M | $72.44M | $-51.63M | $-57.92M | $-140.88M | $182.11M | $-13.81M | $-18.23M | $-26.68M | $-28.58M |
| Low Forecast | $-193.91M | $-199.96M | $-193.91M | $-187.84M | $-192.99M | $-54.61M | $-214.48M | $-24.63M | $-70.44M | $-260.15M | $-211.66M | $-26.34M | $-162.23M | $-28.83M | $-39.53M | $-28.17M | $-32.44M | $-30.83M | $-25.75M | $-26.72M | $-84.39M | $48.29M | $-77.45M | $-86.88M | $-235.35M | $121.41M | $-20.72M | $-27.35M | $-40.02M | $-42.87M |
| Surprise % | - | - | - | - | - | - | - | - | 0.71% | 0.76% | 0.83% | 1.41% | 0.74% | 0.99% | - | 1.00% | 0.95% | 0.90% | 0.84% | 0.94% | 0.08% | 1.37% | 1.07% | 0.92% | 0.27% | 1.49% | 1.33% | 0.96% | 0.83% | 0.97% |
Lexicon Pharmaceuticals's average Quarter net income forecast for Dec 20 is $-67.75M, with a range of $-84.39M to $-50.52M. LXRX's average Quarter net income forecast represents a -182.01% decrease compared to the company's last Quarter net income of $82.60M (Sep 20).
Lexicon Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 3 | 8 | 13 | 11 | 10 | 10 | 9 | 8 | 10 | 9 | 6 | 11 | 6 | 14 | 19 |
| SG&A | - | - | - | - | - | - | - | - | $32.61M | $32.23M | $30.01M | $19.14M | $16.33M | $12.58M | - | $8.49M | $8.85M | $7.30M | $7.94M | $8.26M | $6.43M | $12.00M | $14.11M | $14.69M | $14.56M | $13.90M | $14.26M | $14.11M | $15.58M | $16.75M |
| Avg Forecast | $2.27B | $2.12B | $1.87B | $1.63B | $926.77M | $575.04M | $378.78M | $154.35M | $137.91M | $227.14M | $7.35M | $3.68M | $5.51M | $5.51M | $11.03M | $5.51M | $1.63M | $13.23M | $1.49M | $246.42M | $7.35M | $8.77M | $974.09M | $858.04M | $1.13B | $9.33M | $10.70M | $1.47B | $974.80M | $1.57B |
| High Forecast | $7.34B | $6.83B | $6.03B | $5.27B | $2.99B | $1.48B | $1.22B | $498.55M | $154.13M | $733.64M | $23.74M | $11.87M | $17.81M | $17.81M | $11.03M | $6.55M | $1.96M | $15.88M | $1.77M | $292.98M | $8.74M | $10.52M | $1.16B | $1.02B | $1.35B | $11.19M | $12.84M | $1.74B | $1.17B | $1.88B |
| Low Forecast | $1.04B | $972.69M | $858.91M | $750.86M | $426.10M | $210.06M | $174.15M | $70.97M | $121.68M | $104.43M | $3.38M | $1.69M | $2.53M | $2.53M | $11.03M | $4.43M | $1.30M | $10.58M | $1.20M | $198.20M | $5.91M | $7.01M | $783.50M | $690.17M | $910.30M | $7.46M | $8.56M | $1.18B | $779.84M | $1.25B |
| Surprise % | - | - | - | - | - | - | - | - | 0.24% | 0.14% | 4.08% | 5.21% | 2.96% | 2.28% | - | 1.54% | 5.43% | 0.55% | 5.33% | 0.03% | 0.88% | 1.37% | 0.01% | 0.02% | 0.01% | 1.49% | 1.33% | 0.01% | 0.02% | 0.01% |
Lexicon Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $154.35M, based on 1 Wall Street analysts, with a range of $70.97M to $498.55M. The forecast indicates a 373.38% rise compared to LXRX last annual SG&A of $32.61M (Dec 23).
Lexicon Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 3 | 8 | 13 | 11 | 10 | 10 | 9 | 8 | 10 | 9 | 6 | 11 | 6 | 14 | 19 |
| EPS | - | - | - | - | - | - | - | - | $-0.20 | $-0.21 | $-0.22 | $-0.16 | $-0.16 | $-0.14 | - | $-0.16 | $-0.17 | $-0.16 | $-0.13 | $-0.15 | $-0.04 | $0.77 | $-0.65 | $-0.63 | $-0.48 | $2.13 | $-0.22 | $-0.21 | $-0.26 | $-0.33 |
| Avg Forecast | $-0.16 | $-0.17 | $-0.16 | $-0.15 | $-0.16 | $-0.16 | $-0.18 | $-0.18 | $-0.22 | $-0.21 | $-0.17 | $-0.18 | $-0.13 | $-0.14 | $-0.16 | $-0.17 | $-0.18 | $-0.18 | $-0.16 | $-0.16 | $-0.28 | $0.37 | $-0.61 | $-0.69 | $-0.77 | $-0.23 | $-0.10 | $-0.22 | $-0.40 | $-0.35 |
| High Forecast | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.14 | $-0.05 | $-0.05 | $-0.20 | $-0.06 | $-0.05 | $-0.05 | $-0.04 | $-0.04 | $-0.16 | $-0.12 | $-0.14 | $-0.13 | $-0.12 | $-0.12 | $-0.21 | $0.46 | $-0.45 | $-0.52 | $-0.58 | $-0.17 | $-0.07 | $-0.17 | $-0.32 | $-0.28 |
| Low Forecast | $-0.62 | $-0.64 | $-0.62 | $-0.60 | $-0.62 | $-0.18 | $-0.69 | $-0.70 | $-0.23 | $-0.84 | $-0.68 | $-0.70 | $-0.52 | $-0.55 | $-0.16 | $-0.21 | $-0.23 | $-0.22 | $-0.20 | $-0.20 | $-0.34 | $0.27 | $-0.76 | $-0.87 | $-0.96 | $-0.28 | $-0.12 | $-0.28 | $-0.48 | $-0.42 |
| Surprise % | - | - | - | - | - | - | - | - | 0.92% | 0.98% | 1.26% | 0.89% | 1.20% | 1.00% | - | 0.97% | 0.93% | 0.90% | 0.81% | 0.95% | 0.14% | 2.10% | 1.07% | 0.91% | 0.62% | -9.47% | 2.30% | 0.94% | 0.65% | 0.94% |
According to 10 Wall Street analysts, Lexicon Pharmaceuticals's projected average Quarter EPS for Dec 20 is $-0.28, with a low estimate of $-0.34 and a high estimate of $-0.21. This represents a -135.92% decrease compared to LXRX previous annual EPS of $0.77 (Sep 20).
Lexicon Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.04 | $5.50 | 13650.00% | Buy |
| HEPA | Hepion Pharmaceuticals | $0.72 | $70.00 | 9622.22% | Buy |
| ELEV | Elevation Oncology | $0.63 | $9.00 | 1328.57% | Buy |
| LXRX | Lexicon Pharmaceuticals | $1.61 | $10.00 | 521.12% | Buy |
| XFOR | X4 Pharmaceuticals | $0.65 | $3.67 | 464.62% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| IBRX | ImmunityBio | $3.38 | $8.00 | 136.69% | Sell |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| MREO | Mereo BioPharma Group | $4.32 | $6.75 | 56.25% | Buy |
| ARDX | Ardelyx | $5.60 | $8.75 | 56.25% | Buy |
| MCRB | Seres Therapeutics | $0.95 | $1.25 | 31.58% | Buy |
| HOOK | HOOKIPA Pharma | $4.74 | $3.00 | -36.71% | Buy |
LXRX Forecast FAQ
Is Lexicon Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, Lexicon Pharmaceuticals (LXRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of LXRX's total ratings.
What are Lexicon Pharmaceuticals's analysts' financial forecasts?
Lexicon Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $18.46M (high $56.15M, low $7.99M), average EBITDA is $-32.14M (high $-21.354M, low $-60.142M), average net income is $-174M (high $-90.011M, low $-487M), average SG&A $2.03B (high $6.19B, low $881.28M), and average EPS is $-0.672 (high $-0.29, low $-2.188). LXRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $71.54M (high $231.08M, low $32.89M), average EBITDA is $-49.53M (high $-22.773M, low $-160M), average net income is $-199M (high $-59.223M, low $-776M), average SG&A $7.89B (high $25.48B, low $3.63B), and average EPS is $-0.64 (high $-0.191, low $-2.495).
Did the LXRX's actual financial results beat the analysts' financial forecasts?
Based on Lexicon Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $1.2M, which missed the average analysts forecast of $3.41M by -64.70%. Apple's EBITDA was $-172M, beating the average prediction of $-24.084M by 613.14%. The company's net income was $-176M, missing the average estimation of $-210M by -16.56%. Apple's SG&A was $113.98M, missing the average forecast of $376.08M by -69.69%. Lastly, the company's EPS was $-0.79, beating the average prediction of $-0.786 by 0.53%. In terms of the last quarterly report (Dec 2023), Lexicon Pharmaceuticals's revenue was $702K, missing the average analysts' forecast of $1.25M by -43.88%. The company's EBITDA was $-46.737M, beating the average prediction of $-866K by 5297.14%. Lexicon Pharmaceuticals's net income was $-48.244M, missing the average estimation of $-67.504M by -28.53%. The company's SG&A was $32.61M, missing the average forecast of $137.91M by -76.36%. Lastly, the company's EPS was $-0.2, missing the average prediction of $-0.217 by -7.91%